Genzyme Recognized for Commitment to Multiple Sclerosis Patients
NEC member Genzyme and their CEO David Meeker are being honored for their commitment to patients affected by multiple sclerosis (MS).
The Greater New England Chapter of the National MS Society honored Genzyme and their efforts to support patients at their MileStones Gala this week in Boston. MS is disease that affects the nervous system by damaging the brain and spinal cord. Genzyme offers a variety of drugs to help MS patients, including Aubagio and Lemtrada, along with programs designed to help those living with MS.
Through the Chapter’s Home LINKS program, Genzyme– in partnership with fellow NEC member Suffolk Construction–has created internship opportunities for high school students. The LINKS program seeks to improve the quality of life of those living with MS by offering them in home care management assistance. Genzyme also created the “I Ride MS” campaign to raise awareness of cyclists riding with MS. “I Ride MS” is part of a larger program Bike MS that raises money for MS research through cycling events across the nation. Though MS affects more 2.3 million people globally, Genzyme’s efforts provide a holistic approach for those affected by the disease.
“You learn that there’s so much more to any disease than the drug that you take. As a health care company, we think about how to improve the patients’ lives,” said Meeker.
The New England Chapter of the National MS society serves almost 19,000 people across the region and aspires to help all those affected by MS, including both patients and caregivers. The New England Council thanks Genzyme for the efforts to support patients battling MS and congratulates them on their achievement.